E. A. Markova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
E. A. Markova has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Zoya Alexandrovna Goncharova
Rostov State Medical University, Ministry of Health of Russia
4 shared publications - N. M. Yarosh
Rostov State Medical University
2 shared publications - A. I. Afanas’eVa
Altai State Medical University
1 shared publication - A.M. Prilenskaya
AO MSCH «Neftyanik
1 shared publication - E. Yu. Elchaninova
Altai State Medical University
1 shared publication - Ekaterina Valerievna Popova
City Clinical Hospital No. 24
1 shared publication
Latest Publications
- Open Access
- 30 October 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (5) , 89-95
Opsoclonus-myoclonus-ataxia syndrome in the era of autoimmune encephalitis: reassessment of its rarity and current diagnostic approaches. Cases from clinical practice
Three clinical case reports of opsoclonus-myoclonus-ataxia syndrome (OMAS) in adult patients are presented, illustrating the characteristics of the clinical course, diagnostic challenges and various etiological variants of the condition. In all cases, the onset of the disease was accompanied by the development of ataxia, opsoclonus, myoclonus and cognitive and behavioural disturbances; however, at various stages, the patients were managed under diagnoses of multiple sclerosis, cerebrovascular disease and degenerative disease, which led to a delay in establishing the correct diagnosis. In two patients, the syndrome was paraneoplastic in nature and associated with malignant neoplasms; in one female patient, after the exclusion of a tumour, the condition was classified as seronegative autoimmune OMAS. In all cases, a comprehensive clinical and diagnostic work-up, including magnetic resonance imaging, cerebrospinal fluid analysis, immunological testing and oncological screening, made it possible to exclude alternative causes of the disease and establish the final diagnosis. The initiation of immunosuppressive therapy was accompanied by clinical improvement of varying degrees of severity. The presented case reports emphasize that OMAS in adults remains a rare but likely underestimated condition, requiring high clinical vigilance, timely oncological screening and a comprehensive neuroimmunological work-up. Analysis of these three clinical cases demonstrates the importance of early recognition of the syndrome for the timely initiation of pathogenetic therapy and an improved prognosis.
- 30 October 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (5) , 89-95
Open AccessOpsoclonus-myoclonus-ataxia syndrome in the era of autoimmune encephalitis: reassessment of its rarity and current diagnostic approaches. Cases from clinical practice
Three clinical case reports of opsoclonus-myoclonus-ataxia syndrome (OMAS) in adult patients are presented, illustrating the characteristics of the clinical course, diagnostic challenges and various etiological variants of the condition. In all cases, the onset of the disease was accompanied by the development of ataxia, opsoclonus, myoclonus and cognitive and behavioural disturbances; however, at various stages, the patients were managed under diagnoses of multiple sclerosis, cerebrovascular disease and degenerative disease, which led to a delay in establishing the correct diagnosis. In two patients, the syndrome was paraneoplastic in nature and associated with malignant neoplasms; in one female patient, after the exclusion of a tumour, the condition was classified as seronegative autoimmune OMAS. In all cases, a comprehensive clinical and diagnostic work-up, including magnetic resonance imaging, cerebrospinal fluid analysis, immunological testing and oncological screening, made it possible to exclude alternative causes of the disease and establish the final diagnosis. The initiation of immunosuppressive therapy was accompanied by clinical improvement of varying degrees of severity. The presented case reports emphasize that OMAS in adults remains a rare but likely underestimated condition, requiring high clinical vigilance, timely oncological screening and a comprehensive neuroimmunological work-up. Analysis of these three clinical cases demonstrates the importance of early recognition of the syndrome for the timely initiation of pathogenetic therapy and an improved prognosis.
- Open Access
- 26 March 2026
- Published by Rostov State Medical University in Medical Herald of the South of Russia
- Vol. 17 (1) , 87-96
Clinical and immunological aspects of the first attack of multiple sclerosis (clinically isolated syndrome)
Objective : to identify clinical and immunological predictors of early conversion in patients with CIS. Materials and methods : analysis of medical records and laboratory data of 320 patients, data processing - one- and two-way analysis of variance (ANOVA), nonparametric chi-square test, parametric and nonparametric (Spearman) correlation analysis, Mann-Whitney rank test. Results : age of onset: 13–71 years, mean — 36.4±8 years; Me=36 years. In 60 patients (18.7%) the onset was at the age of 50 years and older. Polyfocal onset was detected in 84.4%, in most patients conversion occurred after 12 months or more. In innate immunity: an increase in CD16+Gr+, % 7.8 [5.2; 9.1], CD14+289+ 12 [4; 20], inversion of the HBT test 155 [139; 171] (p < 0.05). In adaptive immunity: an increase in CD3+HLA DR+, % 3 [2; 5.4], CD8+Gr+ 20 [15; 27], CD19+, % 9 [7; 12], an increase in the CIC, AU. 60 [47;84] (p < 0.05), decrease in CD4+CD25+, % 1.3 [1.0;2.2], CD19+CD5+, % 0.6 [0.3;0.9] (p < 0.05). a wide range of the age of onset was revealed, with a tendency towards an increase in the average age, and prevalence of polyfocal debut. In innate immunity, an increase in monocytes expressing CD14+289+ with a decrease in the ability of antibacterial protection, a decrease in the activation capacity of monocytes, an increase in the cytotoxic functions of natural killers, a decrease in the adaptive reserves of the neutrophil link with inversion of the NBT test. Changes in adaptive immunity lead to inversion of IRI (an increase in cells with a cytotoxic effect, a violation of the B1/B2 lymphocyte ratio and their discoordination). Discoordination of antibody production processes in the humoral immunity. Conclusion : clinical and immunological markers of early conversion of CIS to MS have been identified.
- 26 March 2026
- Published by Rostov State Medical University in Medical Herald of the South of Russia
- Vol. 17 (1) , 87-96
Open AccessClinical and immunological aspects of the first attack of multiple sclerosis (clinically isolated syndrome)
Objective : to identify clinical and immunological predictors of early conversion in patients with CIS. Materials and methods : analysis of medical records and laboratory data of 320 patients, data processing - one- and two-way analysis of variance (ANOVA), nonparametric chi-square test, parametric and nonparametric (Spearman) correlation analysis, Mann-Whitney rank test. Results : age of onset: 13–71 years, mean — 36.4±8 years; Me=36 years. In 60 patients (18.7%) the onset was at the age of 50 years and older. Polyfocal onset was detected in 84.4%, in most patients conversion occurred after 12 months or more. In innate immunity: an increase in CD16+Gr+, % 7.8 [5.2; 9.1], CD14+289+ 12 [4; 20], inversion of the HBT test 155 [139; 171] (p < 0.05). In adaptive immunity: an increase in CD3+HLA DR+, % 3 [2; 5.4], CD8+Gr+ 20 [15; 27], CD19+, % 9 [7; 12], an increase in the CIC, AU. 60 [47;84] (p < 0.05), decrease in CD4+CD25+, % 1.3 [1.0;2.2], CD19+CD5+, % 0.6 [0.3;0.9] (p < 0.05). a wide range of the age of onset was revealed, with a tendency towards an increase in the average age, and prevalence of polyfocal debut. In innate immunity, an increase in monocytes expressing CD14+289+ with a decrease in the ability of antibacterial protection, a decrease in the activation capacity of monocytes, an increase in the cytotoxic functions of natural killers, a decrease in the adaptive reserves of the neutrophil link with inversion of the NBT test. Changes in adaptive immunity lead to inversion of IRI (an increase in cells with a cytotoxic effect, a violation of the B1/B2 lymphocyte ratio and their discoordination). Discoordination of antibody production processes in the humoral immunity. Conclusion : clinical and immunological markers of early conversion of CIS to MS have been identified.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (10) , 92-96
The difficulties with diagnostics of the stiff man syndrome
Stiff-person syndrome (SPS) is a rare immune-mediated disorder of the central nervous system that is characterized by progressive muscle rigidity and painful spasms in the axial and limb muscles, triggered by external stimuli. This disease has significant phenotypic polymorphism, which significantly complicates timely diagnosis and treatment, aggravating disability. Two clinical examples are presented: a patient with the classic phenotype of SPS and a patient with a focal phenotype — stiff leg syndrome. A feature of these cases was atypical symptoms, which made differential diagnosis difficult.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (10) , 92-96
The difficulties with diagnostics of the stiff man syndrome
Stiff-person syndrome (SPS) is a rare immune-mediated disorder of the central nervous system that is characterized by progressive muscle rigidity and painful spasms in the axial and limb muscles, triggered by external stimuli. This disease has significant phenotypic polymorphism, which significantly complicates timely diagnosis and treatment, aggravating disability. Two clinical examples are presented: a patient with the classic phenotype of SPS and a patient with a focal phenotype — stiff leg syndrome. A feature of these cases was atypical symptoms, which made differential diagnosis difficult.
- 5 October 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (9) , 76-82
Assessment of the efficacy and safety of alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis in Russian population
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить степень тяжести и частоту возникновения инфузионных реакций (ИР) на фоне терапии препаратом алемтузумаб у пациентов с высокоактивным течением рассеянного склероза (ВАРС) в российской популяции. МАТЕРИАЛ И МЕТОДЫ В данном ретроспективном исследовании были проанализированы данные 50 пациентов с ВАРС из 6 региональных центров РС России, получивших по два курса алемтузумаба в период с 2018 по 2022 г. РЕЗУЛЬТАТЫ Из всех ИР чаще всего отмечалось появление высыпаний по типу крапивницы (n=27), преимущественно легкой степени тяжести (70,6%). На втором месте по частоте возникновения оказалась головная боль (n=17, 34%). При сравнении группы пациентов, которым проводилась музыкотерапия (МТ), и тех, кто получал алемтузумаб без МТ, статистически значимой разницы частоты и тяжести ИР не было. ЗАКЛЮЧЕНИЕ У всех пациентов были зарегистрированы ИР разной степени выраженности. Отмечалось уменьшение балла по шкале инвалидизации EDSS. МТ не оказала влияния на возникновение ИР и степень их выраженности.
- 5 October 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (9) , 76-82
Assessment of the efficacy and safety of alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis in Russian population
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить степень тяжести и частоту возникновения инфузионных реакций (ИР) на фоне терапии препаратом алемтузумаб у пациентов с высокоактивным течением рассеянного склероза (ВАРС) в российской популяции. МАТЕРИАЛ И МЕТОДЫ В данном ретроспективном исследовании были проанализированы данные 50 пациентов с ВАРС из 6 региональных центров РС России, получивших по два курса алемтузумаба в период с 2018 по 2022 г. РЕЗУЛЬТАТЫ Из всех ИР чаще всего отмечалось появление высыпаний по типу крапивницы (n=27), преимущественно легкой степени тяжести (70,6%). На втором месте по частоте возникновения оказалась головная боль (n=17, 34%). При сравнении группы пациентов, которым проводилась музыкотерапия (МТ), и тех, кто получал алемтузумаб без МТ, статистически значимой разницы частоты и тяжести ИР не было. ЗАКЛЮЧЕНИЕ У всех пациентов были зарегистрированы ИР разной степени выраженности. Отмечалось уменьшение балла по шкале инвалидизации EDSS. МТ не оказала влияния на возникновение ИР и степень их выраженности.